Follicular lymphoma medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 6: Line 6:
The optimal therapy for follicular lymphoma depends on the stage at diagnosis, age, and prognostic scores. The predominant therapy for follicular lymphoma is [[chemotherapy]]. Adjunctive hematopoietic [[stem cell transplantation]] and [[radioimmunotherapy]] may be required.
The optimal therapy for follicular lymphoma depends on the stage at diagnosis, age, and prognostic scores. The predominant therapy for follicular lymphoma is [[chemotherapy]]. Adjunctive hematopoietic [[stem cell transplantation]] and [[radioimmunotherapy]] may be required.
==Medical Therapy==
==Medical Therapy==
* The treatment of follicular lymphoma is based on the stage of the disease.
* The treatment of follicular lymphoma is based on the stage of the disease<ref name="pmid23777769">{{cite journal| author=Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, Sigal BM et al.| title=Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. | journal=Blood | year= 2013 | volume= 122 | issue= 6 | pages= 981-7 | pmid=23777769 | doi=10.1182/blood-2013-03-491514 | pmc=3739040 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23777769  }} </ref><ref name="pmid22211428">{{cite journal| author=McNamara C, Davies J, Dyer M, Hoskin P, Illidge T, Lyttelton M et al.| title=Guidelines on the investigation and management of follicular lymphoma. | journal=Br J Haematol | year= 2012 | volume= 156 | issue= 4 | pages= 446-67 | pmid=22211428 | doi=10.1111/j.1365-2141.2011.08969.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22211428  }} </ref><ref name="pmid24602760">{{cite journal| author=Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P et al.| title=Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. | journal=Lancet Oncol | year= 2014 | volume= 15 | issue= 4 | pages= 424-35 | pmid=24602760 | doi=10.1016/S1470-2045(14)70027-0 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24602760  }} </ref><ref name="pmid27664263">{{cite journal| author=Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M et al.| title=Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | journal=Ann Oncol | year= 2016 | volume= 27 | issue= suppl 5 | pages= v83-v90 | pmid=27664263 | doi=10.1093/annonc/mdw400 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27664263  }} </ref>
.
* For stage 1 and 2, radiotherapy is done.
* For stage 1 and 2, radiotherapy is done.
* For stages 3 and 4, several chemotherapeutic drugs are used for treatment of follicular lymphoma.
* For stages 3 and 4, several chemotherapeutic drugs are used for treatment of follicular lymphoma.

Revision as of 01:17, 28 December 2018

Follicular lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Follicular lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-Ray

CT scan

MRI

Echocardiography or Ultrasound

Biopsy

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Follicular lymphoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Follicular lymphoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Follicular lymphoma medical therapy

CDC on Follicular lymphoma medical therapy

Follicular lymphoma medical therapy in the news

Blogs on Follicular lymphoma medical therapy

Directions to Hospitals Treating Follicular lymphoma

Risk calculators and risk factors for Follicular lymphoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]

Overview

The optimal therapy for follicular lymphoma depends on the stage at diagnosis, age, and prognostic scores. The predominant therapy for follicular lymphoma is chemotherapy. Adjunctive hematopoietic stem cell transplantation and radioimmunotherapy may be required.

Medical Therapy

  • The treatment of follicular lymphoma is based on the stage of the disease[1][2][3][4]

.

  • For stage 1 and 2, radiotherapy is done.
  • For stages 3 and 4, several chemotherapeutic drugs are used for treatment of follicular lymphoma.
  • Chemotherapy is started when there is high tumor bulk load which includes the following:
      • A tumor >7 cm in diameter
      • Three nodes in three distinct areas, each >3 cm in diameter
      • Symptomatic spleen enlargement
      • Organ compression
      • Ascites or pleural effusion

Follicular lymphoma

1. Stage 1 and 2:

  • Radiation doses of 24-30 Gy have been used .

2. High tumor bulk load

2.1. Adult:

    • Preferred regime 1. Bendamustine + rituximab - Day 1: Rituximab 375mg/m2 IV , Days 1 and 2: Bendamustine 90mg/m2 IV over 30–60 minutes. Repeat every 4 weeks for 6 cycles
    • Preferred regime 2. Bendamustine + obinutuzumab - Days 1 and 2: Bendamustine 90mg/m2 IV Days 1, 8, 15 of Cycle 1: Obintuzumab 1000mg IV followed by: Days 1 and 2: Bendamustine 90mg/m2 IV Days 1 of Subsequent Cycles: Obintuzumab 1000mg IV. Repeat every 4 weeks for 6 cycles.
    • Preferred regime 3. RCHOP (Category 1) - Day 0: Rituximab 375mg/m2 IV Day 1: Cyclophosphamide 750mg/m2 IV + doxorubicin 50mg/m2 IV + vincristine 1.4mg/m2 IV (max 2mg) Days 1–5: Prednisone 100mg/m2 orally. Repeat every 3 weeks for 6 to 8 cycles
    • Preferred regime 4. CHOP + obinutuzumab - Day 1: Cyclophosphamide 750mg/m2 IV + doxorubicin 50mg/m2 IV + vincristine 1.4mg/m2 IV (max 2mg) Days 1–5: Prednisone 100mg/m2 orally Days 1, 8, 15 of Cycle 1: Obintuzumab 1000mg IV followed by: Day 1: Cyclophosphamide 750mg/m2 IV + doxorubicin 50mg/m2 IV + vincristine 1.4mg/m2 IV (max 2mg) Days 1–5: Prednisone 100mg/m2 orally Days 1 of Subsequent Cycles: Obintuzumab 1000mg IV. Repeat every 3 weeks for 6 to 8 cycles.
    • Alternate regime 1. CVP + obinutuzumab - Day 1: Cyclophosphamide 750mg/v IV + vincristine 1.4mg/v IV (max 2mg) Days 1–5: Prednisone 40mg/v orally Days 1, 8, 15 of Cycle 1: Obintuzumab 1000mg IV followed by: Day 1: Cyclophosphamide 750mg/v IV + vincristine 1.4mg/v IV (max 2mg) Days 1–5: Prednisone 40mg/m2 orally Days 1 of Subsequent Cycles: Obintuzumab 1000mg IV. Repeat every 3 weeks for 6 to 8 cycles
    • Alternate regime 2. Rituximab, Day 1: Rituximab 375mg/m2 IV. Repeat every 7 days for 4 cycles

2.2. Elderly

  • Preferred regime 1. Rituximab 375mg/m2 IV. Repeat every 7 days for 4 cycles
  • Preferred regime 2. Single agent alkylator ± rituximab - Chlorambucil 0.1mg/kg/day for 45 days then on days 1–15, monthly for 4 months • Rituximab 375mg/m2 weekly for 4 doses, then monthly for 4 infusions

3. Consolidation and extended dosing

  • Rituximab maintenance - Day 1: Rituximab 375mg/m2 IV. Repeat every 8 weeks for 12 cycles for patients initially presenting with high tumor burden.
  • Obinutuzumab maintenance - Day 1: Obinutuzumab 1000 mg IV. Repeat every 8 weeks for 12 cycles.
  • Radioimmunotherapy - 90Yttrium-ibritumomab-tiuxetan 15 MBq/kg (0.4 mCi/kg) single dose after induction with chemotherapy.

High-dose therapy with autologous stem cell rescue and Allogeneic stem cell transplant for highly selected patients.

References

  1. Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, Sigal BM; et al. (2013). "Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience". Blood. 122 (6): 981–7. doi:10.1182/blood-2013-03-491514. PMC 3739040. PMID 23777769.
  2. McNamara C, Davies J, Dyer M, Hoskin P, Illidge T, Lyttelton M; et al. (2012). "Guidelines on the investigation and management of follicular lymphoma". Br J Haematol. 156 (4): 446–67. doi:10.1111/j.1365-2141.2011.08969.x. PMID 22211428.
  3. Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P; et al. (2014). "Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial". Lancet Oncol. 15 (4): 424–35. doi:10.1016/S1470-2045(14)70027-0. PMID 24602760.
  4. Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M; et al. (2016). "Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Ann Oncol. 27 (suppl 5): v83–v90. doi:10.1093/annonc/mdw400. PMID 27664263.